Studies suggest that sodium-glucose cotransporter 2 inhibitors (SGLT-2i) may have neuroprotective properties, opening up new possible directions for the treatment of AD.[9] Specifically, a retrospective study revealed that patients with type 2 diabetes who were prescribed SGLT-2i had a relatively low risk of dementia, with the lowest risk observed among those taking dapagliflozin (DAPA).[10]. This evidence concerns the gene SLC5A2 and dementia.